Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 14/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 14/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139581 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139555 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139565 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139545 | 0.89 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139561 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139569 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139563 | 0.87 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139587 | 0.86 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139566 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12139546 | 0.85 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3274053-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | The Brigham and Women's Hospital, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| WO-2016154362-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20200308176-A1 | CO-CRYSTALS OF NEFLAMAPIMOD (VX-745) | EIP PHARMA, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| WO-2019056003-A1 | CO-CRYSTALS OF NEFLAMAPIMOD (VX-745) | EIP PHARMA, LLC (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| US-7365072-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365072-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | MAPK14 361/4885MAPK13 507/4885MAPK12 273/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885MAPK13 1694/4885MAPK12 1316/4885 |
| US-20200308176-A1 | CO-CRYSTALS OF NEFLAMAPIMOD (VX-745) | PRKX, PRKACA, VRK2 | MAPK14 249/4885MAPK13 360/4885MAPK12 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.